Actavis Inc (ACT) 241.81 $ACT
Actavis Enters New Markets To Boost Profits, Sales
at Investor's Business Daily - Fri Sep 19, 5:08PM CDT
Generic-drugmaker Actavis (ACT) has moved its headquarters to Ireland and is trying to develop its own branded drugs to cut costs and boost revenue. The company, formerly known as Watson Pharmaceuticals, boasts five straight quarters of strong...
Indexes Mixed As Alibaba Closes With 38% Gain
at Investor's Business Daily - Fri Sep 19, 3:30PM CDT
The major averages rose early, with the Dow and S&P 500 marking new intraday highs, but they pared their gains to close near session lows. The Dow Jones industrial average eked out a 0.1% gain to close at a new high, but the Nasdaq eased 0.3% and the...
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Six Leading Stocks Still In Buy Range After Breakouts
at Investor's Business Daily - Thu Sep 18, 5:53PM CDT
Leading stocks across a wide range of sectors have been breaking out or are still in buy range as the Dow industrials and S&P 500 forge ahead to new highs. Actavis (ACT) has advanced since clearing a 229.50 cup-with-handle buy point early this month....
Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today
at The Street - Wed Sep 17, 7:28AM CDT
Some of the top 20 investors are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals, and are pressing Salix to consider selling itself.
3 Reasons Dividend Stock Teva Pharmaceutical Industries Ltd. Could Fall
George Budwell, The Motley Fool - Motley Fool - Tue Sep 16, 10:52AM CDT
Specialty and generic drugmakers have had a banner year in 2014. Top names like Actavis , Mylan, and Teva Pharmaceutical Industries Ltd. , for example, have all beat the broader markets over the past year. This rising tide among generic...
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
APNewsBreak: NY bid to halt Alzheimer's drug swap
By MICHAEL VIRTANEN - AP - Mon Sep 15, 6:11PM CDT
ALBANY, N.Y. (AP) — New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.
IBD 50 Names Hold Gains, But Actionable Charts Scarce
at Investor's Business Daily - Mon Sep 15, 1:37PM CDT
Plenty of IBD 50 names are showing resilience and holding near highs. Damaged charts are the exception, not the rule. That's the good news. The bad news is that new buys aren't easy to find for growth investors looking to put new money to work. A...
3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched iShares Nasdaq Biotechnology Index pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension
PR Newswire - Tue Sep 09, 4:10PM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval.
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
PR Newswire - Tue Sep 09, 7:55AM CDT
On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Is It Time to Buy Actavis plc Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 1:15PM CDT
By all available metrics, the healthcare sector has been performing admirably so far this year. Despite a weak second quarter, most healthcare stocks have seen their share prices climb by double digits for a third straight year. While the sector...
Technical Updates, Upcoming Events, Awards Ceremony, and NDA Filing - Research Reports on Mead Johnson, Philip Morris, Johnson Controls, Actavis and Bristol-Myers
PR Newswire - Mon Sep 08, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mead Johnson Nutrition Company (NYSE: MJN), Philip Morris International, Inc. (NYSE: PM), Johnson Controls Inc. (NYSE: JCI), Actavis plc (NYSE: ACT) and Bristol-Myers Squibb Company (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6279-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product
PR Newswire - Fri Sep 05, 7:00AM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' application for ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI), including those caused by multi-drug resistant Gram-negative bacterial pathogens.
Actavis Enters New Markets To Boost Profits, Sales
at Investor's Business Daily - Fri Sep 19, 5:08PM CDT
Generic-drugmaker Actavis (ACT) has moved its headquarters to Ireland and is trying to develop its own branded drugs to cut costs and boost revenue. The company, formerly known as Watson Pharmaceuticals, boasts five straight quarters of strong...
Indexes Mixed As Alibaba Closes With 38% Gain
at Investor's Business Daily - Fri Sep 19, 3:30PM CDT
The major averages rose early, with the Dow and S&P 500 marking new intraday highs, but they pared their gains to close near session lows. The Dow Jones industrial average eked out a 0.1% gain to close at a new high, but the Nasdaq eased 0.3% and the...
3 Biotechs Investors Should Watch
Brian Orelli, The Motley Fool - Motley Fool - Fri Sep 19, 12:49PM CDT
In the heathcare version of "Where the Money Is", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. In M&A news, Endo International has made an unsolicited bid to acquire ...
Dividend Aristocrats: Time to Buy AbbVie Inc Stock?
George Budwell, The Motley Fool - Motley Fool - Fri Sep 19, 11:32AM CDT
Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans. Not all dividend stocks are great investment vehicles, however. For...
Six Leading Stocks Still In Buy Range After Breakouts
at Investor's Business Daily - Thu Sep 18, 5:53PM CDT
Leading stocks across a wide range of sectors have been breaking out or are still in buy range as the Dow industrials and S&P 500 forge ahead to new highs. Actavis (ACT) has advanced since clearing a 229.50 cup-with-handle buy point early this month....
Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today
at The Street - Wed Sep 17, 7:28AM CDT
Some of the top 20 investors are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals, and are pressing Salix to consider selling itself.
3 Reasons Dividend Stock Teva Pharmaceutical Industries Ltd. Could Fall
George Budwell, The Motley Fool - Motley Fool - Tue Sep 16, 10:52AM CDT
Specialty and generic drugmakers have had a banner year in 2014. Top names like Actavis , Mylan, and Teva Pharmaceutical Industries Ltd. , for example, have all beat the broader markets over the past year. This rising tide among generic...
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
APNewsBreak: NY bid to halt Alzheimer's drug swap
By MICHAEL VIRTANEN - AP - Mon Sep 15, 6:11PM CDT
ALBANY, N.Y. (AP) — New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.
IBD 50 Names Hold Gains, But Actionable Charts Scarce
at Investor's Business Daily - Mon Sep 15, 1:37PM CDT
Plenty of IBD 50 names are showing resilience and holding near highs. Damaged charts are the exception, not the rule. That's the good news. The bad news is that new buys aren't easy to find for growth investors looking to put new money to work. A...
3 Reasons Actavis plc Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 15, 10:50AM CDT
Healthcare and biotechnology stocks have put on another amazing show this year, with the closely watched iShares Nasdaq Biotechnology Index pushing higher by nearly 19% so far. And certain subsectors, including generic and specialty...
Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).
FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension
PR Newswire - Tue Sep 09, 4:10PM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. The committee vote was six to four recommending against approval.
Equity Coverage on Pharma Industry - Zoetis, Actavis, Horizon Pharma, Hospira, and Endocyte
PR Newswire - Tue Sep 09, 7:55AM CDT
On Monday, September 08, 2014, the NASDAQ Composite ended at 4,592.29, up 0.20%, the Dow Jones Industrial Average finished the day 0.15% lower at 17,111.42, and the S&P 500 closed at 2,001.54, down 0.31%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index ended the day at 741.59, up 0.05%, with the index gaining 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT), Horizon Pharma Inc. (NASDAQ: HZNP), Hospira Inc. (NYSE: HSP), and Endocyte Inc. (NASDAQ: ECYT). Free research on these five companies can be accessed at:
Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.
Is It Time to Buy Actavis plc Stock?
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 1:15PM CDT
By all available metrics, the healthcare sector has been performing admirably so far this year. Despite a weak second quarter, most healthcare stocks have seen their share prices climb by double digits for a third straight year. While the sector...
Technical Updates, Upcoming Events, Awards Ceremony, and NDA Filing - Research Reports on Mead Johnson, Philip Morris, Johnson Controls, Actavis and Bristol-Myers
PR Newswire - Mon Sep 08, 7:50AM CDT
Today, Analysts Review released its research reports regarding Mead Johnson Nutrition Company (NYSE: MJN), Philip Morris International, Inc. (NYSE: PM), Johnson Controls Inc. (NYSE: JCI), Actavis plc (NYSE: ACT) and Bristol-Myers Squibb Company (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6279-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product
PR Newswire - Fri Sep 05, 7:00AM CDT
Actavis plc (NYSE: ACT) today confirmed that the U.S. Food and Drug Administration (FDA) has accepted for filing Actavis' application for ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with Complicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI), including those caused by multi-drug resistant Gram-negative bacterial pathogens.
